key: cord-0957810-6ib1060z
authors: Arulkumaran, Nishkantha; Snow, Timothy AC.; Kulkarni, Adarsh; Brealey, David; Rickman, Hannah M.; Rees-Spear, Chloe; Spyer, Moira J.; Heaney, Judith; Garr, Edmund; Williams, Bryan; Cherepanov, Peter; Kassiotis, George; Lunn, Michael; Houlihan, Catherine; McCoy, Laura E.; Nastouli, Eleni; Singer, Mervyn
title: Sex differences in immunological responses to COVID-19: a cross-sectional analysis of a single centre cohort
date: 2021-05-27
journal: Br J Anaesth
DOI: 10.1016/j.bja.2021.05.013
sha: cbbb12e02c55e16723570ec90aaa01e681a5a5c6
doc_id: 957810
cord_uid: 6ib1060z

nan

Editor -COVID-19 is associated with greater severity of illness and mortality in men compared to women. Whilst many lifestyle factors and co-morbidities may be more prevalent among men, most COVID-19 deaths are independently associated with advancing age, male sex, and comorbidity burden. 1, 2 Differences in immune responses to COVID-19 may underpin sex-specific outcome differences. We hypothesised that this might contribute to the pathophysiology of COVID-19, and examined sex differences in physiology, viral loads, SARS-CoV-2-specific antibody titres, and plasma cytokines on hospital admission in patients with COVID-19 who had not received immunomodulatory therapies.

Ethical approval was received from the London-Westminster Research Ethics Committee, the Health Research Authority and Health and Care Research Wales on 2 July 2020 (REC reference 20/HRA/2505, IRAS ID 284088). Blood samples taken from patients ≥18 yr old within five days of admission to University College London Hospitals with polymerase chain reaction proven COVID-19 between 1 March to 30 June 2020 were used for cytokine and antibody quantification (Supplementary data). Outcomes were determined utilizing the World Health Organisation COVID-19 ordinal severity scale, with a score of 1 defined by no limitation of activities, rising to 6 for those requiring noninvasive ventilation and additional organ support, and 10 for death. 3 We included 86 patients, including 30 women and 56 men, with available serum samples (Supplementary Table 1 ). There were no differences in age, days from symptom onset to hospital admission, SpO 2 :FiO 2 ratio, temperature, lymphocyte count, neutrophil count, or viral load between male and female patients. Compared to females, male patients had higher levels of C-reactive proteins (p=0·03), creatinine (p<0·001) and haemoglobin (p<0·001) and a lower platelet count (p=0·01) (Supplementary Figure 1) . Similar proportions of male and female patients had mild disease, diabetes mellitus or hypertension, were smokers, or required organ support. A similar proportion of males and females died in hospital (27% vs. 17%; p=0·27). A total of 55 (65%) patients seroconverted on admission to hospital, with no significant difference in proportion of men and women.

However, levels of G-CSF (p=0·01), GM-CSF (p=0·04), IL-6 (p<0.001), IL-8 (p=0·01), IL-7 (p=0·03), IP-10 (p=0·02), MCP-1 (p=0·049), and IL-10 (p=0·004) were higher in males than females (Figure 1) .

On stratification of patients with mild disease (WHO < 6) or those who progressed to severe disease or death (WHO > 6), differences between sexes persisted for levels of IFN-beta, IL-9, IL-6, IL-10, and IP-10 among patients with mild disease. Females with severe disease had cytokine levels comparable to male patients J o u r n a l P r e -p r o o f (Supplementary Figure 2) . Level of correlation between different cytokine levels, biochemical results, and physiological variables was higher among women compared to men (Supplementary Figure 3) . Correlation between IP-10, IL-6, and IL-10 levels was significant in women. In contrast, correlation between these cytokines was minimal or non-existent among men.

Higher cytokine levels among males compared to females, despite similar age, viral load, degree of hypoxaemia at presentation, and requirement for organ support, may represent an exaggerated host immune response in males. Among female patients with severe disease, levels of cytokines were similar to male patients. This is congruent with recent clinical trials investigating either anti-IL-6 monoclonal antibodies or steroids, where the benefits were seen predominantly in males and in patients with greater illness severity who required advanced respiratory support. 4, 5 Greater expression of virus entry factors (angiotensin-converting enzyme 2 (ACE2) and accessory proteases (TMPRSS2 and CTSL) in airway secretory cells and alveolar type 2 cells may explain the greater cytokine levels in male patients. 6 However, we found similar viral titres (Ct values) between males and females, suggesting that increased viral burden does not completely explain the differences in host response between males and females. In addition to differences in cytokine levels between sexes, poor T cell response is associated with worse disease outcome in male patients, but not in female patients. 7 Therapies aimed at modulating sex hormones show promise and warrant further attention. 8 A higher correlation between most cytokines was seen in female but not male patients, in particular IL-6, IL-10, and IP-10; cytokines associated with increased mortality risk in patients with COVID-19. 9 The clinical implications of this are unclear, but may represent a dysregulated host response to COVID-19 among male patients.

The lack of statistical significance in mortality difference between sexes may be explained by our relatively small sample size. Our data are observational and are hypothesis generating, and limited by the small sample size. We have focused on serological markers on hospital admission but not the trajectory of cytokines over time. Although we cannot exclude the possibility that measured cytokine levels represent different timepoints in the illness between different patients, the times from symptom onset to hospital admission were similar between males and females. Additionally, we lack data on more diverse elements of the immune system including J o u r n a l P r e -p r o o f patients (n=56), including IFN-beta (-0·5636 ± 0·2279; p=0·0154), G-CSF (-0·2029 ± 0·07437; p=0·008), GM-CSF (-0·03877 ± 0·01857; p=0.040), IL-6 (-0·4667 ± 0·1134; p<0·001), IL-8 (-0·3376 ± 0·1289; p=0·011), IL-7 (-0·1602 ± 0·07425; p=0·034), IP-10 (-0·3448 ± 0·1469; p=0·021), MCP-1 (-0·1622 ± 0·08133; p=0·049), and IL-10 (-0·2284 ± 0·07701; p=0·004). Data are presented as mean differences; differences between groups were analysed using Mann-Whitney test. The grey shaded box represents the range seen in healthy volunteers.

J o u r n a l P r e -p r o o f

Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10131 US Veterans With SARS-CoV-2 Infection

Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission

WHO_Working_Group_on_the_Clinical_Characterisation_and_Management_of_COVID-19_infection

A minimal common outcome measure set for COVID-19 clinical research

Dexamethasone in Hospitalized Patients with Covid-19

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label

Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics

Sex differences in immune responses that underlie COVID-19 disease outcomes

Progesterone in Addition to Standard of Care Versus Standard of Care Alone in the Treatment of Men Hospitalized with Moderate to Severe COVID-19: A Randomized, Controlled Pilot Trial

A dynamic COVID-19 immune signature includes associations with poor prognosis

The study protocol and data are available upon reasonable request submitted to the corresponding author.